Literature DB >> 10741173

Serological cross-reactivities between the retroviruses HIV and HTLV-1 and the malaria parasite Plasmodium falciparum.

J Elm1, R Desowitz, A Diwan.   

Abstract

Serum samples from three populations of Papua New Guinea, where Plasmodium falciparum malaria and human T-lymphotropic virus type 1 (HTLV-1) are coendemic at high prevalence rates, showed statistically significant ELISA co-seropositivity and co-seronegativity. Cross-reactivity was further indicated by the presence of 10 bands ranging from 134 kDa to 18 kDa on immunoblots of electrophoresed whole lysate P. falciparum antigen against serum of HTLV-1 seropositive patients from an area where malaria is not present. Similarly, sera from patients positive for human immunodeficiency virus (HIV) from a non-malarious region produced immunoblot bands ranging from 134 kDa to 33 kDa to the P. falciparum antigen. The HTLV-1 and HIV serum samples yielded a number of immunoblot bands when reacted to an electrophoresed human O type red cell membrane antigen, but those bands had no identity to the cross-reactive bands on the P. falciparum antigen immunoblots. Malaria-positive sera from Papua New Guinean subjects presumed to be uninfected with HIV produced a variety of bands, some of intense prominence, to HIV antigen on diagnostic Western blots.

Entities:  

Keywords:  Antibodies; Antigen-antibody Reactions; Biology; Clinical Research; Developing Countries; Diseases; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Laboratory Procedures; Malaria; Melanesia; Oceania; Papua New Guinea; Parasitic Diseases; Physiology; Research Methodology; Research Report; Viral Diseases

Mesh:

Substances:

Year:  1998        PMID: 10741173

Source DB:  PubMed          Journal:  P N G Med J        ISSN: 0031-1480


  5 in total

1.  Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups.

Authors:  K Caglar; R Karakus; C Aybay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.

Authors:  Surender Khurana; James Needham; Susan Park; Bonnie Mathieson; Michael P Busch; George Nemo; Phillipe Nyambi; Susan Zolla-Pazner; Suman Laal; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; James McIntyre; Indira Hewlett; Sherwin Lee; Shixing Tang; Elliot Cowan; Chris Beyrer; Marcus Altfeld; Xu G Yu; Anatole Tounkara; Ousmane Koita; Anatoli Kamali; Nga Nguyen; Barney S Graham; Deborah Todd; Peter Mugenyi; Omu Anzala; Eduard Sanders; Nzeera Ketter; Patricia Fast; Hana Golding
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

3.  Low prevalence rate of indeterminate serological human immunodeficiency virus results among pregnant women from Burkina Faso, West Africa.

Authors:  Dramane Kania; Paulin Fao; Diane Valéa; Clarisse Gouem; Thérèse Kagoné; Hervé Hien; Paulin Somda; Patrice Ouédraogo; Aly Drabo; Sandrine Gampini; Nicolas Méda; Serge Diagbouga; Philippe Van de Perre; François Rouet
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

4.  Limited Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin.

Authors:  Anges Yadouleton; Anna-Lena Sander; Andres Moreira-Soto; Carine Tchibozo; Gildas Hounkanrin; Yvette Badou; Carlo Fischer; Nina Krause; Petas Akogbeto; Edmilson F de Oliveira Filho; Anges Dossou; Sebastian Brünink; Melchior A Joël Aïssi; Mamoudou Harouna Djingarey; Benjamin Hounkpatin; Michael Nagel; Jan Felix Drexler
Journal:  Emerg Infect Dis       Date:  2020-12-01       Impact factor: 6.883

5.  The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm.

Authors:  Derryck B Klarkowski; Joseph M Wazome; Kamalini M Lokuge; Leslie Shanks; Clair F Mills; Daniel P O'Brien
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.